Health (OTC Drugs)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Regulation/Legislation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regulation, Legislation & Health
Valisure Will Continue As 'Inconvenient' Reminder For Change To US Drug Quality ‘Status Quo’
“I think the symptoms of the core disease of quality is not having an independent layer or just not being able to invest more in quality or whatever the other root causes of addressing these quality issues,” says analytical lab president David Light.
EU Firms To Pre-Approve Green Claims Or Face Minimum 4% Annual Turnover Fine
Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive.
US FDA Wants Advisory Committee Duty To Be ‘Enjoyable’
Advisory committee reform efforts include streamlining the selection and onboarding processes, in part to understand that members often have other professional priorities, Principal Deputy Commissioner Namandjé Bumpus said.
The Wait Is Over: US FDA Advisory Committees Returning To In-Person Meetings Come Fall
‘We’re coming back,’ Oncology Center of Excellence Director Richard Pazdur says. Office of New Drugs Director Peter Stein says transition from virtual to in person will be gradual because FDA is trying to be sensitive to adcomm members' need to schedule travel and demands on their time.
Preemption, Constitution Counter New York Law Age-Restricting Some Supplement Sales – CRN
Trade group’s lawsuit filed 13 March in New York alleges NY General Business Law 391-oo, which the state legislature enacted in October 2023 with 22 April effective date, violates US Constitution’s First and 14th amendments plus corresponding articles of the state’s constitution.
Take Care With ‘Health Lite’ Claims
Some advertisers try to avoid scrutiny of regulators and the National Advertising Division when making health-related claims by making a claim “softer.” Annie Ugurlayan, NAD’s assistant director, offers advice on assuring substantiation and a health claim match.
Business Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Deals & Health
Karo Expands Intimate Health Offering With Bayer's Proctosedyl
Sweden's Karo has struck its second deal in six months bringing in the Proctosedyl hemorrhoid brand from Bayer.
C&D Investors, Analysts Not On Same Page
Share price’s recent ride doesn’t track with analysts’ regard for C&D’s results and outlook.
UK’s Dexcel Pharma Snaps Up Eight OTC Brands From Teva
Dexcel Pharma has acquired eight OTC brands from Teva, including Bisodol Indigestion Relief Tablets, erectile dysfunction treatment Liberize and Yeast Vite supplements. Teva told HBW Insight it remains committed to the consumer health market despite a number of recent brand divestments.
Latest From Business Strategies & Health
Stada Grows Twice As Fast As CHC Market In 2023
Stada's local brand focus helped it deliver Consumer Healthcare sales growth of 16% in 2023 ensuring the German firm significantly outpaced the overall market growth rate of 7%.
Valisure Will Continue As 'Inconvenient' Reminder For Change To US Drug Quality ‘Status Quo’
“I think the symptoms of the core disease of quality is not having an independent layer or just not being able to invest more in quality or whatever the other root causes of addressing these quality issues,” says analytical lab president David Light.
EU Firms To Pre-Approve Green Claims Or Face Minimum 4% Annual Turnover Fine
Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive.
Latest From Sales & Earnings & Health
Stada Grows Twice As Fast As CHC Market In 2023
Stada's local brand focus helped it deliver Consumer Healthcare sales growth of 16% in 2023 ensuring the German firm significantly outpaced the overall market growth rate of 7%.
Bayer To Hold On To Consumer Health While It Deals With More Pressing Issues
With Bayer "badly broken in four places," now is not the right time to consider offloading its Consumer Health business, according to group CEO Bill Anderson. Bayer must focus its full attention for the next few years on addressing challenges which include mounting debt and costly litigation before a change to the company's structure can be considered.
‘The Problem Is In-Store’: Kenvue CEO Mongon Lays Out Plan To Kickstart Skin Health & Beauty
The J&J spinout and Neutrogena and Aveeno owner says the challenge facing its Skin Health and Beauty business is not about brand equity or online performance as much as in-store in the US, where it has underperformed. CEO Thibaut Mongon outlined planned investments, expected to drive growth acceleration in Kenvue’s fiscal 2024 second half, at the CAGNY 2024 conference.
Latest From Legal Issues & Health
Cue The Class Actions! Plaintiffs React To Valisure’s Benzene Findings In Acne Drug Products
J&J, Target and Walgreens face class action complaints in California federal courts for economic harms caused by their sale of benzoyl peroxide-containing acne treatments, following Valisure’s 5 March citizen petition to the US FDA on findings of high levels of benzene in such products.
US FDA Should Reload Field Force To Target OTC Adulteration, Former Chief Counsel Hutt Says
Habitually noncompliant companies are laughing at FDA, Peter Barton Hutt says.
FTC Might Need More Illumination On Proposed Rule For Online Consumer Product Reviews
BBB National Programs found FTC’s proposed Trade Regulation Rule on the Use of Consumer Reviews and Testimonials largely effective with some certainty on whether product reviews or customer testimonials are violations of its false advertising standards. But it =expects some clarifications may come in final rule.
Marketing Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Launches & Health
Continued Growth of Self-Care Med Devices Market Rests On Addressing MDR Challenges
A report by AESGP and IQVIA Consumer Health finds that self-care medical devices account for a significant proportion of Europe's OTC market, and as a category is growing rapidly. However, only by “retaining the same favorable market conditions, notably in terms of efficiency, transparency, predictability and innovation” as under previous medical device regulations can this category continue to thrive, they argue.
Perrigo Ships Opill To Stores, But Contraceptive Access Advocates Say It Doesn’t Deliver On Price
First US OTC daily oral contraceptive shipped to major retailers and pharmacies and will be available on shelves nationwide and online later in March. Perrigo says pre-orders for Opill are available currently from select online retailers.
Maxwellia Adds STI Home-Test To UK Lovi Line
UK sexual health specialist Maxwellia continues to expand its UK footprint with an STI home-test launch under the Lovi brand umbrella.
Latest From Ad Campaigns & Health
EU Firms To Pre-Approve Green Claims Or Face Minimum 4% Annual Turnover Fine
Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive.
ASA Files: How Not To Advertise A Digital Health App In The UK
ADHD-management software Happyo falls foul of UK advertising rules in a recent ASA case. The lesson: if in the UK the intended use of a digital health app is the diagnosis of a serious medical condition, supervision by a healthcare professional such as a doctor is likely to be necessary, in which case advertising to the public would also be prohibited.
US Petition Claims Benzene Forms In Benzoyl Peroxide, Requests Market Removal Of Acne Drugs
Valisure recommends FDA request recall and halt sales of products containing benzoyl peroxide due to its propensity to form the benzene. Products include numerous OTC monograph topical formulations as well Rx drugs with an acne indication available through approved applications.
Latest From Ad Complaints & Health
EU Firms To Pre-Approve Green Claims Or Face Minimum 4% Annual Turnover Fine
Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive.
Take Care With ‘Health Lite’ Claims
Some advertisers try to avoid scrutiny of regulators and the National Advertising Division when making health-related claims by making a claim “softer.” Annie Ugurlayan, NAD’s assistant director, offers advice on assuring substantiation and a health claim match.
ASA Files: How Not To Advertise A Digital Health App In The UK
ADHD-management software Happyo falls foul of UK advertising rules in a recent ASA case. The lesson: if in the UK the intended use of a digital health app is the diagnosis of a serious medical condition, supervision by a healthcare professional such as a doctor is likely to be necessary, in which case advertising to the public would also be prohibited.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.